（文章来源：证券日报） 证券日报网讯 9月8日晚间，罗欣药业发布公告称，公司董事会同意聘任武永生先生为公司财务负责 人。 ...

每经AI快讯，罗欣药业（SZ 002793，收盘价：5.69元）9月8日晚间发布公告称，罗欣药业集团股份有 限公司于2025年9月5日收到陈娴女士递交的书面辞职报告。因工作调动原因，陈娴女士申请辞去公司财 务负责人职务，将担任公司创新运营管理办公室副主任。因公司经营发展需要，经公司总经理提名，董 事会提名委员会、审计委员会审查，董事会同意聘任武永生先生为公司财务负责人。 （记者 王晓波） 截至发稿，罗欣药业市值为62亿元。 每经头条（nbdtoutiao）——"中国真正实现了弯道超车"！从美国回来14年，陈智胜亲历中国创新药大 爆发：以前跨国药企不太信任中国数据，但现在不同了 2025年1至6月份，罗欣药业的营业收入构成为：医药工业占比88.11%，医药商业占比10.1%，其他业务 占比1.79%。 ...

罗欣药业集团股份有限公司 关于财务负责人辞职及聘任财务负责人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002793 证券简称：罗欣药业 公告编号：2025-076 公司于 2025 年 9 月 8 日召开第五届董事会第二十九次会议，审议通过了《关 于聘任财务负责人的议案》。因公司经营发展需要，经公司总经理提名，董事会 提名委员会、审计委员会审查，董事会同意聘任武永生先生为公司财务负责人（简 历附后），任期自董事会审议通过之日起至第五届董事会届满之日止。 特此公告。 罗欣药业集团股份有限公司董事会 2025 年 9 月 8 日 1 附件：个人简历 一、财务负责人辞职情况 罗欣药业集团股份有限公司（以下简称"公司"）于 2025 年 9 月 5 日收到 陈娴女士递交的书面辞职报告。因工作调动原因，陈娴女士申请辞去公司财务负 责人职务，辞职后，将担任公司创新运营管理办公室副主任。截至本公告披露日， 陈娴女士未持有公司股份。 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》等有关规定，陈娴女士的辞职报告自送达公司董 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：002793 股票简称：罗欣药业 公告编号：2025-075 罗欣药业集团股份有限公司 第五届董事会第二十九次会议决议公告 三、备查文件 1、董事会提名委员会会议决议。 1 2、董事会审计委员会会议决议。 特此公告。 2025 年 9 月 8 日，罗欣药业集团股份有限公司（以下简称"公司"）第五 届董事会第二十九次会议在山东省临沂高新技术产业开发区罗七路管理中心三 楼会议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结合 的方式召开。会议通知已于 2025 年 9 月 5 日以电话、专人送达、电子邮件等方 式发出。本次会议应出席董事 5 名，实际出席董事 5 名，公司监事、董事会秘书 列席了会议。公司董事长刘振腾先生主持了本次会议。会议的召集、召开符合《中 华人民共和国公司法》等法律法规、规范性文件和《罗欣药业集团股份有限公司 章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于聘任财务负责人的议案》 陈娴女士因工作调动原因申请辞去公司财务负责人的职 ...

| 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 12.59亿 | 10.77亿 | -14.45% | | 归母浄利润（元） | -8870.99万 | 1769.5万 | 119.95% | | 扣非净利润(元) | -1.08亿 | 230.07万 | 102.14% | | 货币资金(元) | 8.98亿 | 2666E | -56.21% | | 应收账款(元) | 4.46亿 | 4.01亿 | -10.12% | | 有息负债(元) | 19.7亿 | 13.77 亿 | -30.10% | | 手利率 | 40.20% | 50.16% | 24.76% | | 净利率 | -9.64% | 2.04% | 121.18% | | 三费占营收比 | 47.50% | 47.24% | -0.54% | | 每股净资产 (元) | 2.1 | 1.3 | -38.12% | | 每股收益(元) | -0.08 | 0.02 | 125.00% | | 每股经营性现金流(元) | -0.13 | 0.2 ...

Core Viewpoint - The company has made significant changes in its capital structure and asset management, including capital increase in a subsidiary and the transfer of equity stakes in another subsidiary, which may impact its financial performance and consolidation scope [5][10]. Group 1: Company Overview - The company did not distribute cash dividends or issue new shares during the reporting period [3]. - The company’s controlling shareholder and actual controller did not change during the reporting period [5]. Group 2: Capital Increase and Related Transactions - The company approved a capital increase of RMB 12 million in its subsidiary, Beijing Health, raising its registered capital from RMB 23.36 million to RMB 35.36 million, increasing the company's ownership from 71.16% to 80.95% [5][6]. - The capital increase was completed with the necessary registration changes [6]. Group 3: Equity Transfer Progress - The company completed the transfer of 70% equity in its subsidiary, Shandong Luoxin Modern Logistics, to a related party, receiving RMB 207.48 million as the first installment of the transfer payment [7][8]. - The performance commitment for the transferred equity includes revenue and net profit targets, with the first-year performance completion rate at 95.76% [9]. Group 4: Public Sale of Subsidiary Equity - The company plans to publicly sell 100% equity of its wholly-owned subsidiary, Lekang Pharmaceutical, through a public listing, but has faced challenges in finding interested buyers [10].

Financial Performance - The company's total revenue for the first half of 2025 was 1.077 billion yuan, a decrease of 182 million yuan compared to the same period last year, representing a year-on-year decline of 14.45% [1] - The net profit attributable to shareholders was 17.695 million yuan, ranking 86th among disclosed peers [1] - The net cash inflow from operating activities was 218 million yuan [1] Financial Ratios - The latest debt-to-asset ratio was 61.94%, ranking 116th among disclosed peers, an increase of 6.71 percentage points compared to the same period last year [3] - The latest gross profit margin was 50.16% [3] - The return on equity (ROE) was 1.25%, ranking 85th among disclosed peers [3] Earnings and Turnover - The diluted earnings per share were 0.02 yuan, ranking 89th among disclosed peers [4] - The total asset turnover ratio was 0.26 times [4] - The inventory turnover ratio was 1.24 times, a decrease of 0.30 times compared to the same period last year, representing a year-on-year decline of 19.54% [4] Shareholder Structure - The number of shareholders was 36,500, with the top ten shareholders holding 558 million shares, accounting for 51.30% of the total share capital [4] - The largest shareholder, Shandong Luoxin Holdings Co., Ltd., held 21.79% of the shares [4]

Proton Pump Inhibitor (PPI) Industry Overview - Proton pump inhibitors (PPIs) are the most potent acid-suppressing medications, widely used for treating acid-related diseases such as peptic ulcers and gastroesophageal reflux disease [1][2] - The Chinese oral PPI market has maintained a scale of over 10 billion yuan from 2018 to 2024, with strong market demand [1][6] - The market has shown volatility due to the implementation of volume-based procurement plans for several generic PPIs, leading to price declines despite increasing sales [1][6] Market Size and Trends - The market size for oral PPIs in China is projected to decline by 10.5% year-on-year in 2024, influenced by price reductions from collective procurement [1][6] - The market for PPIs used for peptic ulcers is valued at 4.8 billion yuan, while the market for those used for gastroesophageal reflux disease is valued at 1.8 billion yuan [6] Product Landscape - As of the end of 2024, there are seven PPI products approved for sale in China, with major products including Rabeprazole, Aplrazole, Esomeprazole, and Omeprazole, collectively holding over 87% market share [1][8] - Rabeprazole leads the market with a share of 27.6%, followed by Aplrazole at 23.7% [1][8] Competitive Landscape - The PPI industry is characterized by intense competition, with numerous companies involved in the production of various PPI products [1][9] - As of July 2025, there are 134 products of Lansoprazole, 106 products of Pantoprazole, and 440 products of Omeprazole produced by over 180 companies in China [1][9] - The leading company for Rabeprazole is Jichuan Pharmaceutical, holding over 30% market share, while AstraZeneca leads the Omeprazole market with a 17.8% share [1][9]

罗欣药业集团股份有限公司 2025 年半年度财务报告 罗欣药业集团股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 罗欣药业集团股份有限公司 2025 年半年度财务报告 财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：罗欣药业集团股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 393,367,329.95 | 456,677,239.94 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 5,250,336.22 | 1,250,336.22 | | 衍生金融资产 | | | | 应收票据 | 16,150,000.00 | | | 应收账款 | 400,799,123.89 | 569,106,113.41 | | 应收款项融资 | 7,979,822.22 | 32,464,517.45 | | 预付款项 | ...

| 编制单位：罗欣药业集团股份有限公司 | | | | | | | | | | 单位：人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 关联关系 | 上市公司核算的 会计科目 | 2025年期初 往来资金余额 | 2025年1-6月往 来累计发生金额 | 2025年1-6月往来 资金的利息 | 2025年1-6月 度偿还累计发 | 2025年6月30日 往来资金余额 | 占用形成原因 | 占用性质 | | | | | | | （不含利息） | （如有） | 生金额 | | | | | 控股股东、实际控制人及其附 | | | | | | | | | | 非经营性占用 | | 属企业 | | | | | | | | | | 非经营性占用 | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其 | | | | | | | | | | 非经营性占用 | | 附属企业 | | | | | | | | | ...